4//SEC Filing
Vivo Ventures V, LLC 4
Accession 0000899243-18-021990
CIK 0001484565other
Filed
Aug 8, 8:00 PM ET
Accepted
Aug 9, 7:12 PM ET
Size
17.5 KB
Accession
0000899243-18-021990
Insider Transaction Report
Form 4
Transactions
- Other
Common Stock
2018-03-07$3.40/sh+53,725$182,665→ 3,941,861 total(indirect: See Footnote) - Other
Common Stock
2018-03-07$3.40/sh+632$2,149→ 46,293 total(indirect: See Footnote) - Other
Common Stock
2018-05-14$3.40/sh+268,629$913,339→ 4,210,492 total(indirect: See Footnote) - Other
Common Stock
2018-05-14$3.40/sh+3,163$10,754→ 49,456 total(indirect: See Footnote)
Vivo Ventures V, LLC
10% Owner
Transactions
- Other
Common Stock
2018-05-14$3.40/sh+268,629$913,339→ 4,210,492 total(indirect: See Footnote) - Other
Common Stock
2018-03-07$3.40/sh+632$2,149→ 46,293 total(indirect: See Footnote) - Other
Common Stock
2018-03-07$3.40/sh+53,725$182,665→ 3,941,861 total(indirect: See Footnote) - Other
Common Stock
2018-05-14$3.40/sh+3,163$10,754→ 49,456 total(indirect: See Footnote)
Vivo Ventures Fund V, L.P.
10% Owner
Transactions
- Other
Common Stock
2018-03-07$3.40/sh+632$2,149→ 46,293 total(indirect: See Footnote) - Other
Common Stock
2018-05-14$3.40/sh+3,163$10,754→ 49,456 total(indirect: See Footnote) - Other
Common Stock
2018-03-07$3.40/sh+53,725$182,665→ 3,941,861 total(indirect: See Footnote) - Other
Common Stock
2018-05-14$3.40/sh+268,629$913,339→ 4,210,492 total(indirect: See Footnote)
Footnotes (7)
- [F1]The shares are held directly by Vivo Ventures Fund V L.P. ("Vivo Ventures Fund V"). The Reporting Person is the sole general partner of Vivo Ventures Fund V, and may be deemed to beneficially own such securities. The Reporting Person holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Edgar Engleman, Albert Cha and Frank Kung, who are managing members of the Reporting Person and disclaim beneficial ownership of the securities held by Vivo Ventures Fund V, except to the extent of any pecuniary interest therein.
- [F2]The shares are held directly by Vivo Ventures V Affiliates Fund, L.P. ("Vivo Ventures V Affiliates Fund"). The Reporting Person is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to be beneficially own such securities. The Reporting Person holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Edgar Engleman, Albert Cha and Frank Kung, who are managing members of the Reporting Person and disclaim beneficial ownership of the securities held by Vivo Ventures Fund V, except to the extent of any pecuniary interest therein.
- [F3]On March 7, 2018, the Reporting Person became entitled to receive the shares pursuant to a "hold-back" provision in the merger agreement dated December 22, 2016, pursuant to which Soleno Therapeutics, Inc. ("Soleno"), acquired all of the outstanding common stock of Essentialis, Inc. ("Essentialis") on March 7, 2017. The merger agreement provided that such shares were to be retained by Soleno and unissued, and to serve as partial security for the indemnification obligations the stockholders of Essentialis, and the shares of Soleno common stock would, for no additional consideration, be issued to the stockholders of Essentialis, subject to any reduction of such shares as a result of satisfying such indemnification obligations. As a result, on the holdback release date of March 7, 2018, the former stockholders of Essentialis, including the Reporting Person, acquired additional shares of Soleno common stock pursuant to the merger agreement.
- [F4](Continued from Footnote 3) The number of shares issuable pursuant to the "hold-back" provision was determined on March 7, 2018, pursuant to a formula set forth in the merger agreement which provided that the number of shares issuable would be four percent (4%) of the total shares issuable in the merger by Soleno. The Reporting Person's right to receive additional shares became fixed and irrevocable on March 7, 2017, the effective date of the merger.
- [F5]On May 14, 2018, the Reporting Person became entitled to receive the shares pursuant to a "milestone earn-out" provision in the merger agreement dated December 22, 2016, pursuant to which Soleno acquired all of the outstanding common stock of Essentialis, Inc. on March 7, 2017. The merger agreement provided that such shares would be issued by Soleno upon the achievement of certain milestone conditions. As a result, on May 14, 2018, the former stockholders of Essentialis, including the Reporting Person, acquired additional shares of Soleno common stock pursuant to the merger agreement. The number of shares issuable pursuant to the "milestone earn-out" provision was determined on May 14, 2018, pursuant to a formula set forth in the merger agreement which provided that the number of shares issuable would be twenty percent (20%) of the total shares issuable in the merger by Soleno.
- [F6](Continued from Footnote 5) The Reporting Person's right to receive additional shares became fixed and irrevocable on March 7, 2017, the effective date of the merger.
- [F7]Share amounts and price are on a post-split basis and reflect the 5:1 reverse stock split effective on October 6, 2017.
Documents
Issuer
SOLENO THERAPEUTICS INC
CIK 0001484565
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001399028
Filing Metadata
- Form type
- 4
- Filed
- Aug 8, 8:00 PM ET
- Accepted
- Aug 9, 7:12 PM ET
- Size
- 17.5 KB